Drug Profile
Research programme: cancer therapeutics - Joyant Pharmaceuticals
Alternative Names: JP 1201; JP-1036Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Joyant Pharmaceuticals
- Class Amides; Peptides; Small molecules
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Non-small cell lung cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer in USA
- 21 Apr 2010 Preclinical pharmacodynamics data presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR-2010)